Jeremy S. Pollock (@bmorecardiology) 's Twitter Profile
Jeremy S. Pollock

@bmorecardiology

Cardiologist, University of Maryland St. Joseph's Medical Center. Specializing in HF, preventative cardiology, and cardiac imaging. All tweets = my own opinion

ID: 854837305177235462

linkhttps://www.umms.org/find-a-doctor/profiles/dr-jeremy-stephen-pollock-md-1124310289 calendar_today19-04-2017 23:21:10

3,3K Tweet

1,1K Followers

540 Following

Stanley Liu, MD, FACC (he/him) (@stanley_liu_md) 's Twitter Profile Photo

One of the most important business lessons to UNLEARN after your medical training is how to be a good soldier. The same attributes that made you flourish as a resident can become a liability as an attending. Learn the mindset you should adopt instead: docempowered.com/the-business-l…

John Asghar MD (@jahangirasgha10) 's Twitter Profile Photo

For those wondering why a simple doctor’s visit takes so long… Or why medical offices can seem so inefficient… Here’s the journey of a single patient chart… and remember only 1/3 of the quality metrics have any clinical relevance… before we’ve even had a chance to talk

For those wondering why a simple doctor’s visit takes so long…
Or why medical offices can seem so inefficient…

Here’s the journey of a single patient chart… and remember only 1/3 of the quality metrics have any clinical relevance…

before we’ve even had a chance to talk
Joseph Marine (@drjmarine) 's Twitter Profile Photo

In our increasingly concentrated healthcare market, physician noncompetes no longer serve a rational economic purpose. More states are waking up to this fact and limiting or banning them. Srihari S. Naidu, MD ACC Advocacy Dutch Rojas John P Erwin III MD MBA MACC (#BigPoppy ) jacc.org/doi/10.1016/j.…

Pablo Corral MD (@drpablocorral) 's Twitter Profile Photo

The #EAS2025 Congress has officially begun, and it kicked off with a crystal-clear, no-nonsense message: LDL-C is CAUSAL This slide leaves no room for ambiguity: •Pathophysiology: LDL is required for plaque development. •Genetics (including familial hypercholesterolemia):

The #EAS2025 Congress has officially begun, and it kicked off with a crystal-clear, no-nonsense message:

LDL-C is CAUSAL

This slide leaves no room for ambiguity:
•Pathophysiology: LDL is required for plaque development.
•Genetics (including familial hypercholesterolemia):
Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 (@drmarthagulati) 's Twitter Profile Photo

Prof Kausik Ray FMedSci #EASCongress2025 🫀LDL/ApoB is atherogenic & our target of Tx 🫀Time matters: cumulative exposure matters- start early& maintain 🫀multiple Tx effective & combination effective: LDL ⬇️ 🫀Post MI: why stepwise? Get LDL ⬇️ early - would ⬇️ MACE

<a href="/ProfKausikRay/">Prof Kausik Ray FMedSci</a> #EASCongress2025 
🫀LDL/ApoB is atherogenic &amp; our target of Tx
🫀Time matters: cumulative exposure matters- start early&amp; maintain
🫀multiple Tx effective &amp; combination effective: LDL ⬇️
🫀Post MI: why stepwise? Get LDL ⬇️ early - would ⬇️ MACE
Jeremy S. Pollock (@bmorecardiology) 's Twitter Profile Photo

Nice Review of options to treat ATTR-CM Tafamadis vs. Acoramidis (Stabilizers)? -- no idea, prob won't ever have trial.. likely whichever insurance will cover Silencer vs. Stabilizer vs. Both? JACC Journals jacc.org/doi/10.1016/j.…

Nice Review of options to treat ATTR-CM

Tafamadis vs. Acoramidis (Stabilizers)?
-- no idea, prob won't ever have trial.. likely whichever insurance will cover

Silencer vs. Stabilizer vs. Both?

<a href="/JACCJournals/">JACC Journals</a> 

jacc.org/doi/10.1016/j.…
Eric Topol (@erictopol) 's Twitter Profile Photo

Just published NEJM A randomized trial of Semaglutide (Ozempic) vs Tirzepatide (Mounjaro, Zepbound) at max doses demonstrates superiority of the latter for weight loss nejm.org/doi/full/10.10…

Just published <a href="/NEJM/">NEJM</a> 
A randomized trial of Semaglutide (Ozempic) vs Tirzepatide (Mounjaro, Zepbound) at max doses demonstrates superiority of the latter for weight loss
nejm.org/doi/full/10.10…
John Mandrola, MD (@drjohnm) 's Twitter Profile Photo

Impressive is the current administration’s choice of ⁦Jay Bhattacharya⁩ ⁦Marty Makary MD, MPH⁩ and ⁦Vinay Prasad MD MPH⁩ to be in key healthcare leadership roles. US health, especially non-communicable disease, is in need of sweeping change. thefp.com/p/ahead-of-the…

Real Doc Speaks (@realdocspeaks) 's Twitter Profile Photo

The HITECH Act exemplified regulatory capture. EHRs were mandated and subsidized to the tune of billions. Here are but a few of the downsides of EHRs: • Decreased the productivity of a profession already in short supply, physicians • Physicians spend hours on the EHR for

Cardiac Trials (@cardiactrials) 's Twitter Profile Photo

SGLT2 inhibition initiation in the acute hospital setting? This trial showed significant benefit — REGARDLESS of ejection fraction — safe, and with incrementally added benefit when started early. EMPULSE Trial, Nature Medicine, 2022 ♥️

SGLT2 inhibition initiation in the acute hospital setting? This trial showed significant benefit — REGARDLESS of ejection fraction — safe, and with incrementally added benefit when started early. EMPULSE Trial, Nature Medicine, 2022 ♥️
Jeremy S. Pollock (@bmorecardiology) 's Twitter Profile Photo

LP(a) is a risk enhancer.. why should this set off diagnostic testing cascade? Aggressive risk factor modification. Drive ApoB down. Don't do unnecessary testing! jacc.org/doi/10.1016/j.… JACC Journals John Mandrola, MD

LP(a) is a risk enhancer.. why should this set off diagnostic testing cascade?

Aggressive risk factor modification. Drive ApoB down. 
Don't do unnecessary testing!

jacc.org/doi/10.1016/j.…

<a href="/JACCJournals/">JACC Journals</a> <a href="/drjohnm/">John Mandrola, MD</a>
Jeremy S. Pollock (@bmorecardiology) 's Twitter Profile Photo

🚴‍♂️🏊‍♂️🏃‍♂️ Sept 27th, I’m taking on the Rock Hall Waterman’s Half Ironman,to raise money for SJMCTowson Donations go directly to support pt care. Thank you for your support! #JustGiving justgiving.com/campaign/jerem…

Jeremy S. Pollock (@bmorecardiology) 's Twitter Profile Photo

In absence of low EF, angina, ventricular arrythmia, in pts with rapid revasc, not sure there is any benefit to BB any longer. Need to change our registry databases, otherwise we will continue to have to utilize BB post MI to avoid "penalties" jacc.org/doi/10.1016/j.…

In absence of low EF, angina, ventricular arrythmia, in pts with rapid revasc, not sure there is any benefit to BB any longer. 

Need to change our registry databases, otherwise we will continue to have to utilize BB post MI to avoid "penalties"

jacc.org/doi/10.1016/j.…